Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunochemotherapy with dendritic cell vaccine in melanoma
2010-020228-23Phase 2Active
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2010
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of TriMix-DC in melanoma, sponsored by Radboud University Medical Center. Primary endpoints: Primary immunogenicity and Primary feasibility. Started Oct 2010; status: active.
02
Drugs
TriMix-DC
03
Conditions
melanoma
Beyond the preview
Go deeper on 2010-020228-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020228-23.